Intermittent androgen suppression. Too good to be true?
The progression of metastatic prostate cancers to an androgen-independent state removes the possibility of further androgen therapy. In response to this, new treatments that do not cause the loss of androgen sensitivity have been sought. Intermittent androgen suppression therapy, an adaptation of the previously used androgen ablation techniques, has shown great promise, comparing favourably with continuous androgen deprivation in pilot studies. It may, therefore, prove to be an excellent treatment, both individually and in combination, although further studies are required.
Abrahamsson
P A
PA
Department of Urology, Lund University Hospital, University of Lund, Sweden. per-anders.abrahamsson@urokir.lu.se
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal